What is Gujarat Kidney And Super Speciality EBITDA Margin %?
Gujarat Kidney And Super SpecialityNSE:GKSL +0.83%18 EBITDA Margin % is 22.92% as of Mar. 2026, which is 17% below its 10-year median of 27.61. GuruFocus rates NSE:GKSL with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Gujarat Kidney And Super Speciality ranks better than 92.37% on this metric.
Gujarat Kidney And Super Speciality (NSE:GKSL) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Gujarat Kidney And Super Speciality EBITDA Margin % Related Terms
Gujarat Kidney And Super Speciality EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Kidney And Super Speciality EBITDA Margin % Chart
Gujarat Kidney And Super Speciality Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
EBITDA Margin %
20.90
21.30
41.50
33.91
Gujarat Kidney And Super Speciality Quarterly Data
NSE:GKSL vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Gujarat Kidney And Super Speciality's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gujarat Kidney And Super Speciality EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Gujarat Kidney And Super Speciality's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Gujarat Kidney And Super Speciality's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Kidney And Super Speciality (NSE:GKSL) has a EBITDA Margin % of 22.92% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gujarat Kidney And Super Speciality and its competitors. This is 17% below median its historical median of 27.61. Over the past decade, Gujarat Kidney And Super Speciality's EBITDA Margin % has ranged from 20.90 to 41.50. According to the industry distribution chart, Gujarat Kidney And Super Speciality ranks #51 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 7.6%.
Is Gujarat Kidney And Super Speciality's EBITDA Margin % too high?
Gujarat Kidney And Super Speciality's current EBITDA Margin % of 22.92% is 17% below median its 10-year median of 27.61. Over the past 10 years, this metric has ranged from a low of 20.90 to a high of 41.50. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Gujarat Kidney And Super Speciality's value of 22.92% is 124.5% above this industry median. Based on the distribution chart, Gujarat Kidney And Super Speciality ranks #51 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Gujarat Kidney And Super Speciality has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Gujarat Kidney And Super Speciality's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Gujarat Kidney And Super Speciality ranks #51 out of 668 companies for EBITDA Margin %. This places Gujarat Kidney And Super Speciality in the top 8% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Gujarat Kidney And Super Speciality's value of 22.92% is 124.5% above this benchmark. Historically, Gujarat Kidney And Super Speciality's own EBITDA Margin % has ranged from 20.90 to 41.50 over the past decade. While the company's 10-year median is 27.61 vs. the industry median of 10.21, Gujarat Kidney And Super Speciality has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gujarat Kidney And Super Speciality's current EBITDA Margin % of 22.92% is 124.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gujarat Kidney And Super Speciality and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gujarat Kidney And Super Speciality's current EBITDA Margin % is 22.92%, which is 17% below median its own 10-year median of 27.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Kidney And Super Speciality stock overvalued right now?
Gujarat Kidney And Super Speciality (NSE:GKSL) has a current EBITDA Margin % of 22.92%. The current EBITDA Margin % is 22.92%, which is 17% below median its 10-year median of 27.61 and 124.5% above the Healthcare Providers & Services industry median of 10.21. Gujarat Kidney And Super Speciality's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Gujarat Kidney And Super Speciality (NSE:GKSL), the current EBITDA Margin % is 22.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gujarat Kidney And Super Speciality Business Description
Gujarat Kidney And Super Speciality Ltd is engaged in the business of operating a chain of mid-sized multispeciality hospitals in central Gujarat and providing integrated healthcare services, with a focus on secondary and tertiary care. It offers a range of healthcare services, including General Medicine, General Surgery, Laparoscopic Surgery, Urology, Cardiology, Nephrology, and many more. The company operates in a single segment, namely Medical and Healthcare Services. It generates a substantial portion of revenue from its services to inpatients. Geographically, it operates only in India.
18GF Score
Get the complete analysis for NSE:GKSL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GKSL has been successfully added to your 